ChromaDex (NASDAQ:CDXC – Get Free Report) and Curaleaf (OTCMKTS:CURLF – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.
Volatility and Risk
ChromaDex has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Curaleaf has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for ChromaDex and Curaleaf, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ChromaDex | 0 | 0 | 2 | 0 | 3.00 |
| Curaleaf | 0 | 0 | 1 | 0 | 3.00 |
Institutional and Insider Ownership
15.4% of ChromaDex shares are owned by institutional investors. Comparatively, 0.0% of Curaleaf shares are owned by institutional investors. 9.6% of ChromaDex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares ChromaDex and Curaleaf”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ChromaDex | $83.57 million | 3.13 | -$4.94 million | ($0.02) | -172.00 |
| Curaleaf | $1.35 billion | 1.40 | -$281.20 million | ($0.35) | -8.31 |
ChromaDex has higher earnings, but lower revenue than Curaleaf. ChromaDex is trading at a lower price-to-earnings ratio than Curaleaf, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ChromaDex and Curaleaf’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ChromaDex | -1.58% | -4.68% | -2.50% |
| Curaleaf | -18.59% | -14.75% | -5.19% |
Summary
ChromaDex beats Curaleaf on 10 of the 12 factors compared between the two stocks.
About ChromaDex
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
About Curaleaf
Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.
